Meeting Overview & Strategic Context
Why this meeting matters and what you need to walk away with.
Meeting Objective
Establish AI Partnership
Position AREEP as Tabuk's strategic AI partner for product chatbots, HCP engagement automation, and digital transformation across their 17-country MENA footprint.
Opportunity Size
$500K+
Estimated initial contract value across AI chatbot, medical rep agent, and HCP engagement platform. Expandable to group level (Astra Industrial).
Strategic Fit
Near-Perfect Match
Tabuk operates across the exact MENA markets AREEP is targeting — KSA, UAE, Jordan, Kuwait, Qatar. Their Vision 2030 alignment makes them receptive to AI investment.
🎯 Your Primary Goal Today
Get agreement on a paid Proof-of-Concept (PoC) for one AI agent — ideally the Product Information AI Chatbot for HCPs. Target: SAR 150,000–250,000 pilot with 60-day delivery. Walk in with a concrete proposal, not just ideas.
⚡ Key Leverage Point
Tabuk is expanding aggressively — new oncology, biosimilar, and diabetes products in 2025–2026. Each new product launch is a natural AI chatbot opportunity. They NEED scalable HCP engagement. This is pain meeting solution.
What You're Selling Today
💬
Product #1
Product AI Chatbot
HCP-facing chatbot with real-time drug information, dosing, interactions
🤖
Product #2
Medical Rep AI Agent
Automates rep preparation, call summaries, HCP visit intelligence
📊
Product #3
HCP Engagement OS
Omnichannel HCP profiling, next-best-action, CRM intelligence layer
⚙️
Product #4
Pharma Ops Automation
Pharmacovigilance, regulatory reporting, adverse event auto-processing
Tabuk Pharmaceuticals Intelligence Brief
Everything you need to know about Tabuk before walking into the room.
1994
Founded in Riyadh
17
Countries MENA & Africa
2,400+
Employees across 4 sites
2B+
Base units produced annually
Product Portfolio (12 Therapeutic Areas)
| Therapeutic Area | AI Opportunity | Priority |
|---|---|---|
| Anti-Infectives | Antibiotic guidance chatbot (Vibativ® launch) | High |
| Cardiovascular | HCP education agent, dosing assistant | High |
| Diabetes | Patient & HCP engagement (Althera T2D deal) | High |
| Oncology / Immuno | ADI-PEG20 (ADZODI) launch chatbot — new entry | Critical |
| Gastrointestinal | K-CAB® (Tegoprazan) MENA rollout support | Critical |
| Respiratory / Allergy | Patient triage, HCP content automation | Medium |
| Central Nervous System | Rep training agent, protocol chatbot | Medium |
| Musculoskeletal / Bone | Osteoarthritis HCP tool (VOLT01 pipeline) | Medium |
| Dermatology | Ustekinumab biosimilar BAT2206 launch | High |
| Pain Management | Pharmacovigilance automation | Medium |
| Urology / Nephrology | Specialty HCP agent | Low |
| Hospital Products | Clinical decision support chatbot | Medium |
2025–2026 Strategic Moves
New Product Launches (High AI Need)
🔬 ADI-PEG20 (ADZODI) — oncology, rare cancer treatment, KSA + GCC
💊 Vibativ® (telavancin) — antibiotic for HABP/VABP, KSA launch Sep 2025
🩺 K-CAB® (Tegoprazan) — GI product expanded to more MENA markets
🧬 BAT2206 (Ustekinumab biosimilar) — Stelara® biosimilar, KSA
🩸 Rolontis® (Eflapegrastim) — oncology supportive, Hanmi partnership
🍬 Althera T2D combo therapy — diabetes, MENA markets
💊 Vibativ® (telavancin) — antibiotic for HABP/VABP, KSA launch Sep 2025
🩺 K-CAB® (Tegoprazan) — GI product expanded to more MENA markets
🧬 BAT2206 (Ustekinumab biosimilar) — Stelara® biosimilar, KSA
🩸 Rolontis® (Eflapegrastim) — oncology supportive, Hanmi partnership
🍬 Althera T2D combo therapy — diabetes, MENA markets
Parent Company Context
Astra Industrial Group (Listed)
Tabuk is a fully-owned subsidiary. Any AI deal could be pitched as a group-level transformation play — expanding your contract scope significantly. Manufacturing sites in KSA (Tabuk + Dammam), Sudan, Algeria.
Technology Stack They Currently Use
Microsoft IIS
Angular 4
K2 Platform
Freshservice
No known AI layer yet
Traditional pharma CRM assumed
🔍 Tech Stack Insight for Your Pitch
They're running legacy Microsoft stack + process automation (K2). This means: (1) they're familiar with workflow tools, (2) likely no AI in production yet, (3) AREEP can position as the AI intelligence layer that sits on top of their existing systems — low disruption, high value. Emphasize API-first integration approach.
AI Solutions Portfolio for Tabuk
The specific solutions to present, mapped to Tabuk's actual business needs.
Product AI Chatbot
HCP Product Information Agent
An AI-powered conversational agent trained on Tabuk's full product portfolio. Physicians, pharmacists, and hospital staff can ask questions about dosing, contraindications, drug interactions, side effects, and clinical data — in Arabic and English — and get instant, compliant, referenced answers.
Tabuk Use Case
Launch-ready chatbot for Vibativ®, K-CAB®, and ADZODI. Embed on website, WhatsApp, and HCP portals. Reduces medical information hotline calls by ~60%.
Arabic + English Regulatory Compliant 60-day Delivery
Medical Rep AI Agent
Intelligent Sales Force Enablement
AI assistant for Tabuk's 2,400+ person commercial team. Before every HCP visit, the agent prepares the rep: key talking points, HCP preferences, objection handlers, and product updates. After each visit, it auto-generates call notes, updates CRM, and recommends next-best-action.
Tabuk Use Case
With 17-country operations, rep productivity is critical. AI can reduce admin time by 40%, improve call quality scores, and ensure consistent product messaging across all markets.
CRM Integration Voice to Text Multi-country
HCP Engagement OS
Omnichannel Physician Intelligence
A full omnichannel HCP engagement platform. Profiles each healthcare provider across digital channels, visit history, prescribing behavior, and preferences. AI engine generates next-best-action recommendations for reps and medical affairs teams.
Tabuk Use Case
AREEP's core product. Directly maps to Tabuk's need to scale HCP engagement across KSA, UAE, Jordan — especially for new specialty launches in oncology and immunology.
AREEP Core Product Vision 2030 Fit MENA-native
Pharmacovigilance AI
Automated Adverse Event Processing
AI agent that automatically reads, extracts, and processes adverse event reports — from emails, forms, calls, and documents. Routes them to the correct team with priority classification. Dramatically reduces pharmacovigilance team workload and improves regulatory compliance timelines.
Tabuk Use Case
Tabuk has a dedicated pharmacovigilance section on their website — this is a live concern. With new specialty launches, AE volume will increase. This is a compliance-driven, budget-assured purchase.
Compliance-Critical SFDA-aware
AI Medical Affairs Agent
Scientific Engagement Automation
An AI agent that helps medical affairs teams respond to HCP scientific inquiries at scale. Trained on clinical trial data, published studies, and product dossiers. Generates compliant, referenced responses, manages unsolicited request queues, and tracks engagement.
Tabuk Use Case
As Tabuk enters oncology and biosimilars, the volume of KOL and HCP medical inquiries will surge. This agent can handle 80% of queries without human intervention.
KOL Engagement Evidence-based AI
💡 Recommended Pitch Sequence for This Meeting
Start with the Product AI Chatbot — it's tangible, fast to implement, and tied to their current new product launches (Vibativ®, K-CAB®, ADZODI). Then expand to the HCP Engagement OS as the strategic vision. Use Pharmacovigilance AI as the "compliance hook" if they need a defensible budget reason. End with the broader AREEP platform vision as the long-term roadmap.
Suggested Meeting Agenda
A structured 90-minute flow to move from rapport to commitment.
0:00
Opening & Introductions
Set agenda, confirm objectives. Open with a Tabuk-specific insight: "We looked into your recent Vibativ® and ADZODI launches — congratulations on the oncology move. Today we want to show how AI can accelerate those launches."
0:10
Discovery — Tabuk's AI Readiness
Ask 4–5 key discovery questions about their current HCP engagement model, rep productivity pain points, and digital transformation priorities. LISTEN more than you talk.
0:25
AREEP Overview (5 min max)
Brief company intro — MENA-native AI OS for pharma. Mention current clients/markets. Position as a specialist, not a generic AI vendor. "We only work in pharma, only in MENA."
0:30
Solution Demo — Product AI Chatbot
Live demo or demo video of the product chatbot. Use a Tabuk product if possible (e.g., simulate questions about Vibativ® or K-CAB®). Make it real, not hypothetical.
0:50
Vision — Full AI Transformation Roadmap
Show the bigger picture: how AREEP's HCP Engagement OS, Medical Rep Agent, and Pharmacovigilance AI create a complete AI-powered commercial operation. Present a 12-month roadmap slide specific to Tabuk.
1:05
ROI & Business Case
Present the numbers: rep productivity gains, HCP engagement improvement, pharmacovigilance cost reduction. Use MENA pharma benchmarks. Show Vision 2030 alignment for budget justification.
1:15
Objections & Q&A
Address concerns on data privacy (SFDA compliance), Arabic NLP quality, implementation timeline, and pricing. Have answers ready — see Objections tab.
1:25
PoC Proposal & Close
Present the 60-day Product AI Chatbot PoC. SAR 150K–250K pilot scope. Clear deliverables, success metrics, and go-live plan. Ask for a decision-maker commitment, not just a follow-up.
🔑 Meeting Success Metrics
You've succeeded if you walk out with: (1) Named internal champion, (2) IT / procurement contact, (3) Agreement to receive PoC proposal in writing, (4) Confirmed follow-up meeting date within 2 weeks. The gold standard is a verbal commitment to the pilot.
Talk Tracks & Key Messages
Exact language to use at key moments in the conversation.
Opening Hook
"Tabuk is at a genuinely exciting inflection point — you're entering oncology, launching biosimilars, expanding into more MENA markets, and you've got six new products in the pipeline. The commercial teams that win in that environment aren't just the biggest — they're the most intelligent. AREEP exists to give pharma companies like Tabuk an AI brain for their commercial operation."
📌 Use at the very start after introductions. Tie it to their actual 2025–2026 launches.
Product Chatbot Value Prop
"Every time you launch a new product — Vibativ®, K-CAB®, ADZODI — your medical information team gets flooded with HCP inquiries. Dosing questions, interaction checks, clinical data requests. Our AI chatbot handles 80% of those inquiries automatically, in Arabic and English, 24/7, with full audit trails for SFDA compliance. Your medical affairs team focuses on the 20% that truly needs them."
📌 Use when presenting the product chatbot. Quantify the 80% figure as industry benchmark.
Vision 2030 Alignment
"Saudi Arabia's Vision 2030 has a specific pillar around digital health and pharmaceutical sector advancement. AI investment in commercial pharma is exactly what the Kingdom is incentivizing. Tabuk — as the largest private pharma company in KSA — has an opportunity to set the benchmark. Not just adopt AI, but lead it."
📌 Use when discussing the strategic rationale. Resonates strongly with Saudi leadership teams.
MENA-Native Advantage
"Most AI platforms are built in the US or Europe and then adapted for MENA. We built AREEP from day one for this region — Arabic NLP, SFDA compliance, Gulf cultural context, local cloud infrastructure. When we say we understand your market, we mean it literally. We operate in the same markets you do."
📌 Use when competitors come up or when they ask about regional expertise.
PoC Close
"I don't want to ask you to commit to a major platform decision today. What I do want to propose is a 60-day pilot — we build the product AI chatbot for one or two of your current launches, we define three clear success metrics together, and after 60 days you decide if you want to scale. The investment is SAR 150,000 to 250,000 — it's designed to be a risk-free way to see the value before you make a larger commitment."
📌 Use at the close. This reduces perceived risk and makes a 'yes' much easier to give.
When Asked About ROI
"Industry benchmarks show that AI-assisted pharma commercial teams reduce rep admin time by 35–40%, improve HCP call quality by 28%, and reduce medical information query handling cost by up to 60%. For a company with Tabuk's footprint across 17 countries and 2,400 employees, even a 20% improvement in commercial efficiency translates to millions in value. The chatbot pilot alone typically pays for itself within the first 90 days of a new product launch."
📌 Use when they ask 'what's the ROI?' or 'how do we justify this to management?'
Discovery Questions
Click any question to reveal why it matters and what answer to listen for.
Strategic Discovery
▶
Q01
Where is AI transformation on your executive agenda for 2026?
Listen for: Is this top-down driven (CEO/VP) or bottom-up? If it's top-down, budget is easier. If bottom-up, you need to help them build the internal business case. Also identifies if there's an existing AI initiative you might complement or compete with.
▶
Q02
As you expand into oncology and biosimilars, what's your biggest HCP engagement challenge?
This is a product-specific pain question. They'll likely mention: HCPs don't have time for reps, medical information volume, complex clinical data communication. Each answer maps directly to one of your AI products.
▶
Q03
How are your medical reps currently preparing for HCP visits — and what does that process look like?
If the answer is "manually, using PDFs and emails," that's a direct opening for the Medical Rep AI Agent. If they have a system, ask how satisfied they are with it. Reveals both the pain and current investment level.
▶
Q04
What does your current medical information / HCP inquiry handling process look like?
This reveals the direct opportunity for the product chatbot. Volume of queries, response times, team size, languages needed. Quantify the pain: "how many queries per week?" gets you ROI data.
▶
Q05
With 17 country operations, how do you currently ensure consistent product messaging across markets?
This is almost always a pain point for multi-market pharma. Inconsistent messaging, localization challenges, and compliance gaps are common. Positions AREEP's centralized AI with market-specific customization as the solution.
Technical & Budget Discovery
▶
Q06
Have you piloted or evaluated any AI tools in your commercial or medical affairs functions before?
Identifies prior AI experience and any failed projects (which become objections). If they say "we tried X and it didn't work," that's critical intelligence. Also reveals sophistication level and who owns the evaluation.
▶
Q07
Who would be the key stakeholders for an AI initiative like this — IT, commercial, medical affairs?
Maps the buying committee. In pharma, AI decisions typically involve: Commercial VP, Medical Director, IT/Digital, and Legal/Compliance. You need all of them eventually. Find out who's in the room and who's missing.
▶
Q08
What data infrastructure do you currently use — CRM, ERP, HCP databases?
Technical due diligence. They use K2 Platform and Freshservice per public data. Understanding what HCP data they have helps you scope the integration and demonstrate that AREEP can connect to their existing systems.
▶
Q09
What would a successful AI pilot look like to you — what metrics would make you say 'this worked'?
This is the most powerful question in the meeting. It gets them to define success, which you then use to design your PoC. Listen carefully — these become your contractual KPIs. Common answers: query response time, HCP satisfaction score, rep admin time saved.
▶
Q10
Is there budget allocated for digital transformation / AI for the remainder of 2026?
Direct budget qualification. Frame it as: "We want to make sure we scope a pilot that fits your current planning cycle." If budget isn't allocated, shift to helping them build the internal business case. If it is, ask about timeline and decision process.
Objection Handling Playbook
The most likely objections you'll face and exactly how to handle them.
⚠️ Objection
"We're concerned about patient data privacy and SFDA regulatory compliance with AI systems."
✅ Your Response
"This is exactly the right question. AREEP is built specifically for MENA pharma, which means SFDA compliance, data residency within Saudi Arabia, and full audit trails are built in — not added on. We can share our data processing agreements and compliance architecture. For the chatbot specifically, it handles published, approved product information only — no PHI involved in phase one."
⚠️ Objection
"We already have vendors — Microsoft, Freshservice. Why do we need another AI platform?"
✅ Your Response
"AREEP doesn't replace Microsoft or Freshservice — we integrate with them. We're the pharma-specific intelligence layer on top of your existing infrastructure. Microsoft gives you productivity tools; AREEP gives you pharma commercial AI that understands HCP engagement, product data, medical compliance. It's complementary, not competitive."
⚠️ Objection
"How good is the Arabic NLP? Our HCPs communicate primarily in Arabic."
✅ Your Response
"We designed AREEP for Arabic from day one — not as a translation layer. Our models are trained on Arabic medical and pharmaceutical content. We can demonstrate this live — ask me a product question in Arabic right now, or we can schedule a technical demo with your medical affairs team. We're also happy to include Arabic NLP quality as a PoC success metric."
⚠️ Objection
"We're not sure we're ready for AI yet. We need to get our data in order first."
✅ Your Response
"That's a common concern, but the product chatbot is actually the perfect starting point precisely because it doesn't require your internal data to be clean. It's trained on your approved product materials — SmPCs, IFUs, clinical summaries — which you already have. We can be live in 60 days without touching your CRM or HCP database. Data maturity can be built as we go."
⚠️ Objection
"Can you prove ROI? How do we justify this investment to our group (Astra Industrial)?"
✅ Your Response
"We'll build you a custom ROI model together. But here's the headline: pharma companies using AI chatbots for HCP medical information reduce query handling costs by 55–65% and improve response time from 2–3 days to under 2 minutes. For Tabuk's scale — with 6 new product launches and 17 markets — that's a clear, quantifiable return. We'll put the numbers in writing in the PoC proposal."
⚠️ Objection
"We need to evaluate other vendors. Can you send us a proposal and we'll review?"
✅ Your Response
"Absolutely — and we're confident in a competitive evaluation. Before I send a generic proposal, let me ask: what are the 2–3 criteria that matter most to you in this decision? I want to make sure the proposal is tailored to what Tabuk actually needs, not a template. And can we schedule a follow-up in two weeks to walk through it together, so you can ask questions directly?"
Post-Meeting Action Plan
What to do in the 48 hours after the meeting to maintain momentum.
Within 2 Hours
Send Meeting Recap
Email summary of what was discussed, key points of agreement, and your understanding of their priorities. Keep it brief — 5 bullet points max. Confirms professionalism and keeps you top of mind.
Within 48 Hours
Send PoC Proposal
Deliver a structured 8–12 page PoC proposal: scope for the Product AI Chatbot for Vibativ® or K-CAB®, 60-day timeline, 3 success KPIs they defined, investment (SAR 150K–250K), and a one-page implementation roadmap.
Within 1 Week
Follow-Up Call
Short 20-minute call to review the proposal together. Answer questions. Try to get IT/procurement on the call. Your goal: get the proposal approved to move to legal/procurement review stage.
Information to Collect Today
☐ Names and roles of everyone in the room
☐ Decision-maker vs. influencer vs. champion
☐ IT / procurement contact for vendor onboarding
☐ Budget cycle and approval process
☐ Timeline for decision (target date)
☐ Current CRM system name and vendor
☐ Which product launch is highest priority (PoC scope)
☐ Legal / compliance requirements for data handling
☐ Existing AI / digital health vendor relationships
☐ CEO/VP sponsor name for follow-up
☐ Decision-maker vs. influencer vs. champion
☐ IT / procurement contact for vendor onboarding
☐ Budget cycle and approval process
☐ Timeline for decision (target date)
☐ Current CRM system name and vendor
☐ Which product launch is highest priority (PoC scope)
☐ Legal / compliance requirements for data handling
☐ Existing AI / digital health vendor relationships
☐ CEO/VP sponsor name for follow-up
PoC Proposal Structure
📄 Executive Summary — 1 page, Tabuk-specific
🔍 Problem Statement — their HCP engagement challenge
💡 Proposed Solution — Product AI Chatbot scoped to 2 products
📅 60-Day Implementation Plan — week-by-week milestones
📊 Success Metrics — 3 KPIs agreed in the meeting
💰 Investment & ROI — SAR pricing + payback period
🔐 Compliance & Security — SFDA, data residency
🚀 Scale Roadmap — Phase 2 & 3 vision
🔍 Problem Statement — their HCP engagement challenge
💡 Proposed Solution — Product AI Chatbot scoped to 2 products
📅 60-Day Implementation Plan — week-by-week milestones
📊 Success Metrics — 3 KPIs agreed in the meeting
💰 Investment & ROI — SAR pricing + payback period
🔐 Compliance & Security — SFDA, data residency
🚀 Scale Roadmap — Phase 2 & 3 vision
🏆 Long-Term Account Vision (12-Month Roadmap)
Month 1–2: PoC — Product AI Chatbot for 1–2 products (Vibativ® + K-CAB®)
Month 3–5: Expand chatbot to full product portfolio (12 therapeutic areas)
Month 6–8: Medical Rep AI Agent rollout for KSA sales force
Month 9–12: Full HCP Engagement OS deployment + Pharmacovigilance AI
Year 2 Target: Group-level Astra Industrial deal — extend to Sudan, Algeria, UAE, Jordan operations
Month 3–5: Expand chatbot to full product portfolio (12 therapeutic areas)
Month 6–8: Medical Rep AI Agent rollout for KSA sales force
Month 9–12: Full HCP Engagement OS deployment + Pharmacovigilance AI
Year 2 Target: Group-level Astra Industrial deal — extend to Sudan, Algeria, UAE, Jordan operations